4,4',4'',4'''-(Porphine-2,3,5,21(23H)-tetrayl)tetra(benzene-1-sulfonic acid) | 92000-20-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四吡咯及其衍生物
• 英文名称: 4,4',4'',4'''-(Porphine-2,3,5,21(23H)-tetrayl)tetra(benzene-1-sulfonic acid)
• 英文别名: 4-[2,3,21-tris(4-sulfophenyl)-23H-porphyrin-5-yl]benzenesulfonic acid
• CAS: 92000-20-9
• 化学式: C₄₄H₃₀N₄O₁₂S₄
• 分子量: 935.0
• InChiKey: VYNKGAFTRFGUNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  64
• 可旋转键数：
  8
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  298
• 氢给体数：
  5
• 氢受体数：
  14

文献信息

• [EN] PHOTODYNAMIC THERAPY AND DIAGNOSIS USING A CHLORIN E4 ZINC COMPLEX<br/>[FR] THÉRAPIE ET DIAGNOSTIC PHOTODYNAMIQUES
  申请人：PHOTO DIAGNOSTIC DEVICES PDD L

  公开号：WO2009040411A1

  公开（公告）日：2009-04-02

  The present invention relates to a process of preparing chlorin e4-Zn complex. The present invention also relates to a pharmaceutical composition comprising chlorin e4-Zn complex for the treatment of, for example, cancer. The present invention further relates to methods of treating and diagnosing, for example, cancer by photodynamic therapy or photodynamic diagnosis.

  本发明涉及一种制备氯原卟啉e4-Zn配合物的方法。本发明还涉及一种包含氯原卟啉e4-Zn配合物的药物组合物，用于治疗癌症等疾病。本发明还涉及通过光动力疗法或光动力诊断等方法治疗和诊断癌症的方法。
• COMPOSITIONS, APPARATUS, SYSTEMS, AND METHODS FOR RESOLVING ELECTRONIC EXCITED STATES
  申请人：HALLSTAR INNOVATIONS CORP.

  公开号：US20140044654A1

  公开（公告）日：2014-02-13

  The present disclosure relates, according to some embodiments, to molecules, including conjugated fused polycyclic molecules, that may receive excited state energy from other molecules (e.g., light-absorbing molecules) or directly from the irradiation sources. According to some embodiments, the disclosure relates to molecules, including conjugated fused polycyclic molecules, that may resolve (e.g., quench, dissipate) excited state energy, normally by way of releasing it as heat. (e.g., as heat). Conjugated fused polycyclic molecules of various structures are disclosed including Formula III: The disclosure further relates to methods of use and/or therapy using molecules of Formulas I, II, and/or III.

  本公开涉及一些实施例，涉及分子，包括共轭融合多环分子，这些分子可以从其他分子（例如吸收光的分子）或直接从辐射源接收激发态能量。根据一些实施例，本公开涉及分子，包括共轭融合多环分子，这些分子可以通过释放为热量的方式解决（例如，熄灭，耗散）激发态能量。披露了具有各种结构的共轭融合多环分子，包括式III。本公开还涉及使用式I、II和/或III的分子进行治疗和/或疗法的方法。
• Conjugate comprising a neurotensin receptor ligand
  申请人：3B Pharmaceuticals GmbH

  公开号：EP2954933A1

  公开（公告）日：2015-12-16

  The present invention is related to a conjugate comprising a structure of general formula (I)         [TM1] - [AD1] - [LM] - [AD2] - [TM2]     (I), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target; wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (II): wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2-adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9-carboxylic acid; R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3C8)cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK is (C2-C5)alkylidene; R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the following formula (III) wherein ALK' is (C2-C5)alkylidene; R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl; and R7 is a bond; or a pharmacologically acceptable salt, solvate or hydrate thereof.

  本发明涉及一种包含一般式（I）结构的结合物，其中TM1是第一靶向基团，第一靶向基团能够结合到第一个靶标，AD1是第一适配基团或者不存在，LM是连接基团或者不存在，AD2是第二适配基团或者不存在，TM2是第二靶向基团，第二靶向基团能够结合到第二个靶标；其中第一靶向基团和/或第二靶向基团是式（II）化合物之一：其中R1选自氢、甲基和环丙基甲基组成的群；AA-COOH是选自2-氨基-2-环戊烷羧酸、环己基甘氨酸和9-氨基-双环[3.3.1]壬烷-9-羧酸组成的氨基酸；R2选自（C1-C6）烷基、（C3-C8）环烷基、（C3-C8）环烷基甲基、卤素、硝基和三氟甲基的群；ALK是（C2-C5）烷基亚基；R3、R4和R5各自独立地选自氢和（C1-C4）烷基，但是在R3、R4和R5中的一个符合以下式（III）：其中ALK'是（C2-C5）烷基亚基；R6选自氢和（C1-C4）烷基；R7是键；或其药理学上可接受的盐、溶剂或水合物。
• Method to prepare porphyrin nanoparticles and its application as oxidation catalyst
  申请人：——

  公开号：US20030232982A1

  公开（公告）日：2003-12-18

  The present invention relates to a method to prepare porphyrin nanoparticles and its application as oxidation catalyst. Mixing solvent techniques was used to prepare porphyrin nanoparticles. The sizes of the resulted porphyin nanoparticles are in the range of 1-1000 nm. The resulted porphyrin nanoparticles were characterized by DLS, AFM and UV-Vis. The nanoparticles are stable in air from weeks to months and has been successfully transferred to Al 2 O 3 and silica gel surface. The present invention also related to a method to use nanoparticles of porphyrins as catalyst for epoxidation reactions of olefins and hydroxylation reactions of saturated hydrocarbons. By loading the nanoparticles onto the surface of Al 2 O 3 and silica gel, excellent catalytic activities were obtained in oxidation reactions.

  本发明涉及一种制备卟啉纳米颗粒及其作为氧化催化剂的应用方法。采用混合溶剂技术制备卟啉纳米颗粒，所得到的卟啉纳米颗粒的尺寸在1-1000纳米范围内。所得到的卟啉纳米颗粒通过DLS、AFM和UV-Vis进行表征。这些纳米颗粒在空气中稳定，可以保持数周至数月，并成功地转移到Al2O3和二氧化硅凝胶表面。本发明还涉及一种使用卟啉纳米颗粒作为烯烃环氧化反应和饱和烃羟化反应催化剂的方法。通过将纳米颗粒载入Al2O3和二氧化硅凝胶表面，可以获得优异的氧化反应催化活性。
• HOLLOW NANOPARTICLES AND USES THEREOF
  申请人：Cid-Arregui Angel

  公开号：US20110052496A1

  公开（公告）日：2011-03-03

  Aspects of the invention provide hollow nanoparticles and uses thereof. In particular, the invention provides membrane-enclosed vesicles comprising a truncated form of an HBsAg S protein lacking one or two of its amino-terminal transmembrane domains.

  本发明提供了空心纳米颗粒及其用途。具体而言，本发明提供了膜包裹的囊泡，其中包括缺失其一个或两个氨基末端跨膜结构域的HBsAg S蛋白的截短形式。